Health Professional Radio - Podcast

Dr. Jan Wehkamp, M.D. Vice President and Gastroenterology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC, talks about data from the Phase 3b, STARDUST study, showing that two doses of STELARA® (ustekinumab) induced clinical remission in two-thirds of patients with Crohn’s Disease (CD). STARDUST is the first study to compare a treat to target approach with standard of care in CD and using endoscopy to guide use of medication.